← Writing

Parkinson's Disease Is to Lewy Body Disease as Alzheimer's Disease Is to Frontotemporal Dementia

Parkinson'sAlzheimer'sfrontotemporal dementianeuropathology

In 1912, German neurologist Friedrich Lewy discovered eosinophilic intracytoplasmic inclusions in the brains of Parkinson's Disease (PD) patients. These are now named after him and known as Lewy bodies, which for decades remained a histological curiosity attached to the clinical syndromes of parkinsonism (bradykinesia, rigidity, and resting tremor) [19, 21]. Almost 70 years later, in 1997, Spillantini et al. identified alpha-synuclein as the main constituent of Lewy bodies [12]. Soon, an entire family of diseases — Lewy Body Diseases (LBD), or synucleinopathies — was constructed around this protein, with PD as the core anchor of LBD [13, 21].

Just six years before Lewy, the Bavarian psychiatrist Alois Alzheimer showed the world the case of Auguste Deter. In her brain, Alzheimer found "military foci" and "dense bundles of fibrils," which we now know to be amyloid plaques and tau neurofibrillary tangles that define the disease [11, 33]. The fibrils are composed of hyperphosphorylated tau protein, now known to correlate closely with Alzheimer's dementia symptoms, including progressive loss of declarative and episodic memory and impairments in language and behavior [4, 7]. This protein links Alzheimer's disease to a broader pathological family too: tauopathies, which include diseases like progressive supranuclear palsy and a large subset of frontotemporal lobar degeneration cases (FTLD-tau) — the pathology behind much of clinical Frontotemporal Dementia (FTD) [10, 15, 23].

Is it the case, then, that tau pathology connects Alzheimer's Disease to Frontotemporal Dementia the way alpha-synuclein connects Parkinson's to dementia with Lewy bodies? Ultimately, though some elements of this analogy are true, it doesn't hold overall. Parkinson's Disease can reasonably be treated as one particular clinical manifestation within the broader spectrum of Lewy Body Disease, but Alzheimer's Disease and Frontotemporal Dementia do not have this subset relationship. They are generally distinct constructs, albeit with overlapping presentations and shared mechanisms.

Defining LBD and FTD

LBD is a spectrum of pathology characterized by Lewy bodies and Lewy neurites — aggregates composed mostly of phosphorylated alpha-synuclein — which includes Parkinson's Disease, Parkinson's Disease Dementia (PDD), and Dementia with Lewy Bodies (DLB) [19, 21]. A subset of the clinical manifestation of LBD is Lewy Body Dementia, which also becomes "LBD" in many sources; to keep the two distinct, I'll write Lewy Body Disease as LBD and Lewy Body Dementia in full. This dementia subset includes DLB and PDD [11, 13].

Frontotemporal dementia is a clinical syndrome marked mainly by progressive changes in behavior, function, language, and memory [1, 5]. It results from frontotemporal lobar degeneration, which, as the name suggests, involves degeneration of the frontal and temporal lobes caused by proteins like tau, TDP-43 (transactive response DNA-binding protein 43 kDa), and the FET family of proteins that move between nucleus and cytoplasm to control transcription and splicing [10, 15, 23].

Evidence For

Both sides of the analogy share a lot of clinical territory. For Lewy body diseases, PD, PDD, and DLB overlap across motor, cognitive, psychiatric, and sleep domains [13, 25]. Parkinsonism (bradykinesia, resting tremor, rigidity) is the defining feature of PD but also develops in 80% of DLB patients. Visuospatial impairment appears early across all three diagnoses; attention and processing speed in particular are affected more than memory, in contrast with AD [13, 25]. Visual hallucinations appear in 60–80% of DLB patients and 30–40% of PD patients. This shared clinical territory appears on the AD/FTD side as well: though AD normally begins with episodic memory impairment and FTD normally begins with behavioral change, by late stage both converge into progressive, global cognitive impairment [24, 26, 28], including executive dysfunction in working memory and problem-solving. This shared clinical territory is real, but as the next section will show, it emerges from structurally different causes.

The second piece of evidence for the analogy is that both PD and AD are, in some ways, the central, historically familiar disease within a broader protein-defined field. PD is the central member of the synucleinopathy field, since synucleinopathies are defined by pathological aggregates of alpha-synuclein in neurons and glia, and this protein connects PD to PDD and DLB [12, 13, 21]. In parallel, AD is the most common tauopathy, defined by the combined presence of extracellular amyloid plaques and intraneuronal tau neurofibrillary tangles [7, 11, 33]. Tau, much like alpha-synuclein, connects AD to the broader tauopathy field, which includes a subset of FTD: FTLD-tau, which includes entities like Pick disease (also, interestingly, first distinguished from Alzheimer's by Alois Alzheimer himself), progressive supranuclear palsy, corticobasal degeneration, and MAPT-associated disease [10, 23]. Familial FTLD-tau is caused by mutations in MAPT, the gene encoding tau [10, 14]. The protein overlap is not perfect, however — AD also requires amyloid pathology, and FTLD includes a whole other subset of non-tau diseases [11, 15]. Both AD and PD are almost siblings in how each relates to its proteinopathy family: both are examples of proteostasis failure (misfolded protein aggregation), oxidative stress, mitochondrial dysfunction, and neuroinflammation [17, 18].

Third, in both pairs, single genetic lesions produce phenotypes that span both the eponymous disease (PD/AD) and its umbrella disease (LBD/FTD). In the PD/LBD case, SNCA — the gene encoding alpha-synuclein itself — is the clearest example [21, 30]. SNCA duplications, in which someone inherits an extra copy and overproduces the protein from birth, can produce autosomal-dominant disease that appears clinically as either PD or another LBD, like DLB [29]; autopsies of these patients show brains full of Lewy bodies around the cortex, even though the clinical labels differ [21, 29]. Similarly, GBA, which encodes the lysosomal enzyme glucocerebrosidase important for clearing damaged alpha-synuclein, shows mutations that increase the risk of both PD and other LBDs, like DLB and PDD, by roughly fivefold [3, 22, 34]. Correspondingly, though much more weakly, on the AD/FTD side, heritable FTD accounts for about 10% of all FTD cases — a much larger proportion than familial AD, at only about 1% [10, 14]. The main genes associated with FTD are MAPT, GRN, and C9orf72 [10, 14, 23]. Mutations in MAPT cause FTLD-tau, producing AD-adjacent pathology and symptoms (tau protein and cognitive impairment) but not actual AD pathology [10, 23]. GRN mutations and C9orf72 expansions cause FTLD-TDP type A and B, which are also occasionally, though more tangentially, AD-like [14, 23]. Type A is characterized by short dystrophic neurites and crescent/oval neuronal cytoplasmic inclusions (NCIs) mainly in the upper neocortical layers; type B by diffuse granular NCIs distributed evenly across all cortical layers, with far fewer dystrophic neurites [20, 23]. Neither is AD pathology, though both are occasionally mistaken for it clinically. In 2019, a pathology called LATE (Limbic-predominant Age-related TDP-43 Encephalopathy) was described — caused by the same protein as much FTD, TDP-43, but presenting with the symptoms of late-onset Alzheimer's: gradual memory decline in an elderly patient [6, 16, 31]. Ultimately, in both pairs, single-gene mutations can blur clinical boundaries, though SNCA shows that PD and DLB are essentially the same disease dressed up differently, while MAPT and C9orf72 show that FTLD may dress up like AD but is still FTLD underneath.

Evidence Against the Analogy

The main problem with the analogy is that it claims a "set theory" relationship that does not exist. On one side, Lewy Body Diseases genuinely encompass Parkinson's Disease and Parkinson's Disease Dementia [13, 21]. Parkinson's is defined by Lewy body pathology in the substantia nigra, so the relationship is one of containment — PD is a subset of LBDs [13, 19]. The analogy claims AD stands in the same relationship to FTD, but that is simply not true. These are two parallel clinical and pathological entities, with separate criteria, symptoms, and anatomical distributions [1, 32]. AD patients are not FTD patients; rather, they are siblings within the broader subset of neurodegenerative dementia, sharing substantial overlap in clinical territory and genetics, as noted above. The containment relationship echoed by PD and LBD would work if we instead compared AD to tauopathies or amyloidopathies (though partially, since AD involves both), or to neurodegenerative dementias generally (but only trivially) [11, 15].

Even setting this first problem aside, LBD and FTD, the two umbrella terms in the analogy, are still asymmetrical: one is unified, the other heterogeneous. LBD is molecularly grounded [13, 21]. After Spillantini et al. identified alpha-synuclein as the major constituent of Lewy bodies, the family was assembled from clinical entities sharing this protein — PD, PDD, DLB, and others — giving LBD a single defining protein that aggregates in a broadly consistent way [12, 19]. FTD is different: it was constructed from a unifying clinical-anatomical observation, the progressive degeneration of the frontal and temporal lobes resulting in behavioral and language syndromes [1, 32]. The first unifying definition, the Lund-Manchester criteria, focused on symptoms ("behavioural disorder," "speech disorder") and impacts ("microscopic characteristics"), without mentioning the proteins that cause it [32]. In some sense, historical discoveries for PD/LBD have increasingly unified the underlying biology. For a century, neurologists observed a collection of clinical entities that shared something: in 1919 Konstantin Tretiakoff first coined "corps de Lewy" (PD); in 1961 Okazaki described cortical Lewy bodies in dementia patients (PDD); and in 1976 Kosaka described diffuse Lewy body disease. The discovery of alpha-synuclein as the main constituent of Lewy bodies unified all these fragments [12, 21] — a discovery that came just a few days after Polymeropoulos et al. identified SNCA mutations causing familial PD [30]. On the AD/FTD side, by contrast, the 1994 Lund-Manchester criteria formalized frontotemporal dementia, unifying Pick's disease and other dementias under one clinical umbrella [32]. But in 2006, Neumann et al. identified TDP-43 as the major protein in most cases of FTD [20, 27], and in 2009 the FUS protein was also found to aggregate in FTD. Progressive discoveries have only fragmented this once-unified field further [15, 23].

This asymmetry has practical consequences too. LBD's molecular unity means biomarker development can target alpha-synuclein alone — for example, alpha-synuclein seed amplification assays and αSyn PET tracers [9, 21] — which can identify the entire family, though it becomes correspondingly hard to distinguish between the different diseases within LBD [2, 19]. FTD's heterogeneity, by contrast, means no single biomarker captures all its variants: tau PET tracers will identify FTLD-tau but miss FTLD-TDP, for example [9, 14, 15].

Third, one of the main distinctions between PD and the other forms of LBD is fundamentally temporal. Clinicians classify PD, DLB, and PDD using the "one-year rule": if dementia develops before motor symptoms, by one year or less, that's DLB; the other way around, it's PDD [13, 25]. For AD versus FTD, the distinction is different in kind, not just timing. First, location: AD begins in the medial temporal lobe and affects episodic memory, while FTD begins in the frontal lobe and affects either behavior (bvFTD) or language first [1, 5, 33]. Second, in direct response to the molecular argument above (that both are tauopathies), FTD is actually characterized by at least three distinct FTLD molecular pathologies: FTLD-tau makes up only about 40% of FTD pathologies, FTLD-TDP (associated with GRN mutations) makes up around 50%, and FTLD-FUS composes most of the remaining 10% [10, 15]. This proportion undercuts the argument that tau is a bridge between AD and FTD, since the majority of FTD cases actually involve TDP-43 [10, 27]. AD, by contrast, has an established molecular signature: amyloid and tau are present in essentially all cases [11, 33].

Finally, there is a difference in genetic architecture between the two pairs. The genetic machinery behind PD and other forms of LBD is very consistent [8, 30]. AD, on the other hand, is dominated by sporadic, late-onset disease, accounting for over 99% of cases, while FTD is more heritable — around 30% of patients have a strong family history, and 10% carry one of the three autosomal-dominant genes discussed above [10, 14]. Even in familial early-onset Alzheimer's, the core genetic machinery is APP, PSEN1, and PSEN2, which make up the amyloidogenic pathway, showing that the genetic core of AD is amyloidopathic rather than tauopathic [4, 18].

Conclusion

It's striking that Alois Alzheimer, in his Über eigenartige Krankheitsfälle des späteren Alters, was able to distinguish Alzheimer's from Pick's, drawing the boundary between AD and FTD almost a century ago. PD and AD were both named and discovered in eras when clinicians had only symptoms and microscopes, with no access to twenty-first-century molecular pathology. In one case, they categorized the disease by grouping PD with other conditions sharing a molecular pathology — alpha-synuclein; in the other, they grouped AD with other diseases sharing a clinical outcome — dementia. At heart, this grouping is different in kind: one is bottom-up, the other top-down. We have now shown PD to be a genuine subset of Lewy Body Diseases, while Alzheimer's is increasingly distinct, molecularly, from Frontotemporal Dementia [10, 13, 15, 21]. There are still, of course, a host of similarities in both pairs, which is exactly why the analogy arose — but understanding how the analogy fails is critical to how we diagnose and treat these diseases. LBD's molecular unity enables biomarker programs to target a single responsible protein, something that remains impossible for FTD [9, 15, 21].

References

  1. Bang, J., Spina, S., & Miller, B. L. (2015). Frontotemporal dementia. The Lancet, 386(10004), 1672–1682.
  2. Beach, T. G., et al. (2024). Clinicopathological heterogeneity of Lewy body diseases: the profound influence of comorbid Alzheimer's disease. medRxiv.
  3. Blauwendraat, C., et al. (2019). Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. Brain, 143(1), 234–248.
  4. Bloom, G. S. (2014). Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurology, 71(4), 505–508.
  5. Boeve, B. F., Boxer, A. L., Kumfor, F., Pijnenburg, Y., & Rohrer, J. D. (2022). Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations. The Lancet Neurology, 21(3), 258–272.
  6. Bogdanovic, N., et al. (2025). Alzheimer mimicry: LATE and PART. Journal of Neural Transmission.
  7. Busche, M. A., & Hyman, B. T. (2020). Synergy between amyloid-β and tau in Alzheimer's disease. Nature Neuroscience, 23(10), 1183–1193.
  8. Chia, R., et al. (2021). Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 53(3), 294–303.
  9. Chouliaras, L., & O'Brien, J. T. (2023). The use of neuroimaging techniques in the early and differential diagnosis of dementia. Molecular Psychiatry, 28(10), 4084–4097.
  10. Clark, D. G. (2024). Frontotemporal dementia. Continuum (Minneapolis, Minn.), 30(6), 1642–1672.
  11. DeTure, M. A., & Dickson, D. W. (2019). The neuropathological diagnosis of Alzheimer's disease. Molecular Neurodegeneration, 14(1), 32.
  12. Estaun-Panzano, J., et al. (2022). Monitoring α-synuclein aggregation. Neurobiology of Disease, 176, 105966.
  13. Gomperts, S. N. (2016). Lewy body dementias: dementia with Lewy bodies and Parkinson disease dementia. Continuum (Minneapolis, Minn.), 22(2, Dementia), 435–463.
  14. Greaves, C. V., & Rohrer, J. D. (2019). An update on genetic frontotemporal dementia. Journal of Neurology, 266(8), 2075–2086.
  15. Grossman, M., et al. (2023). Frontotemporal lobar degeneration. Nature Reviews Disease Primers, 9(1), 40.
  16. Hiya, S., et al. (2023). Cognitive symptoms progress with limbic-predominant age-related TDP-43 encephalopathy stage and co-occurrence with Alzheimer disease. Journal of Neuropathology & Experimental Neurology, 83(1), 2–10.
  17. Ho, P.-C., et al. (2024). TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: from pathomechanisms to therapeutic strategies. Ageing Research Reviews, 100, 102441.
  18. Karran, E., & De Strooper, B. (2022). The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nature Reviews Drug Discovery, 21(4), 306–318.
  19. Kon, T., et al. (2019). Neuropathology of Lewy body disease: clinicopathological crosstalk between typical and atypical cases. Neuropathology, 40(1), 30–39.
  20. Kwong, L. K., et al. (2007). TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. Acta Neuropathologica, 114(1), 63–70.
  21. Leak, R. K., et al. (2024). Current insights and assumptions on α-synuclein in Lewy body disease. Acta Neuropathologica.
  22. Liu, L., et al. (2022). Effect of GBA gene variants on clinical characteristics of dementia with Lewy bodies: a review and meta-analyses. Neurological Sciences, 43(6), 3541–3550.
  23. Mann, D. M. A., & Snowden, J. S. (2017). Frontotemporal lobar degeneration: pathogenesis, pathology and pathways to phenotype. Brain Pathology, 27(6), 723–736.
  24. Mariano, L. I., et al. (2019). Disinhibition in frontotemporal dementia and Alzheimer's disease: a neuropsychological and behavioural investigation. Journal of the International Neuropsychological Society, 26(2), 163–171.
  25. McKeith, I. G., et al. (2017). Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology, 89(1), 88–100.
  26. Mohaupt, P., et al. (2024). Blood-based biomarkers and plasma Aβ assays in the differential diagnosis of Alzheimer's disease and behavioral-variant frontotemporal dementia. Alzheimer's Research & Therapy, 16(1), 271.
  27. Neumann, M., et al. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 314(5796), 130–133.
  28. Nguyen, H.-D., et al. (2023). Deep grading for MRI-based differential diagnosis of Alzheimer's disease and frontotemporal dementia. Artificial Intelligence in Medicine, 144, 102636.
  29. Nishioka, K., et al. (2009). Expanding the clinical phenotype of SNCA duplication carriers. Movement Disorders, 24(12), 1811–1819.
  30. Polymeropoulos, M. H., et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276(5321), 2045–2047.
  31. Ramanan, V. K., & Day, G. S. (2024). LATE, hippocampal sclerosis, and primary age-related tauopathy. Continuum (Minneapolis, Minn.), 30(6), 1726–1743.
  32. The Lund and Manchester Groups. (1994). Clinical and neuropathological criteria for frontotemporal dementia. Journal of Neurology, Neurosurgery & Psychiatry, 57(4), 416–418.
  33. Trejo-Lopez, J. A., et al. (2021). Neuropathology of Alzheimer's disease. Neurotherapeutics, 19(1), 173–185.
  34. Walton, R. L., et al. (2024). Role of GBA variants in Lewy body disease neuropathology. Acta Neuropathologica, 147(1), 54.